Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization analysis.
The manufactured product will be used in proprietary immunization protocols at IPA’s Canadian facility. These studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mAb) responses—a crucial step toward translational development.
“This is the natural next step in our journey from AI discovery to real-world validation,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “We’ve shown that HYFT technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. Now we’re now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? This is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases.”
The science behind the step:
- AI Discovery → Manufacturing: HYFT-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes.
- Validated Safety & Immunogenicity: In silico screens confirmed immune activation potential (B- and T-cell responses), structural stability, and comprehensive safety against host proteomes.
- Now Entering Immunization Studies: The product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development.
A platform approach, not just a vaccine:
This progression highlights IPA’s end-to-end advantage: combining AI-native discovery with in-house wet-lab validation. With regulators like the U.S. FDA encouraging predictive, human-relevant approaches that reduce reliance on animal testing, ImmunoPrecise’s in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine R&D.
By applying the same methodology across pathogens, IPA is positioning its LENSai/HYFT platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets.